ProCE Banner Activity

Targeting TROP-2 in Breast Cancer: How Experts Are Integrating TROP-2 ADCs Into Clinical Practice

Slideset

Download this slideset from a live meeting series for the multidisciplinary team to get up to date on the latest clinical data informing optimal use of TROP-2 antibody–drug conjugates in the treatment of advanced triple-negative breast cancer and HR-positive/HER2-negative metastatic breast cancer, including management of key adverse events associated with these agents.

Released: October 11, 2023

Share

Faculty

Aditya Bardia

Aditya Bardia, MD, MPH

Director, Breast Cancer Research
Associate Professor
Harvard Medical School
Attending Physician
Massachusetts General Hospital
Boston, Massachusetts

Erika P. Hamilton

Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.